Heart watch: simple blood test may shield cancer patients from therapy damage
NCT ID NCT06337097
First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times
Summary
This study is testing whether checking troponin levels in the blood before each dose of immune checkpoint therapy can help catch heart problems early. 980 cancer patients will either get regular troponin monitoring or standard care. The goal is to see if this approach lowers heart-related side effects from treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Troponin surveillance (blood test)
- What this could lead to
- If successful, this could show that routine heart monitoring during immunotherapy helps catch and prevent heart problems early.
- What could go wrong
- This is an observational study, not a treatment trial. It may not prove that monitoring actually reduces heart issues, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE CHECKPOINT THERAPY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.